Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology. Its mRNA technology could allow the firm to compete in a wide range of ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

Moderna's financial challenges are compounded by a slowing adoption of its second product, the RSV vaccine, and an experimental cytomegalovirus (CMV) vaccine that has yet to meet early efficacy ...

Moderna has also filed for approval for a combination Covid-flu shot. And the company anticipates efficacy data this year from late-stage studies of vaccines for seasonal flu and norovirus ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

The COVAIL trial reveals that neutralizing antibody titers correlate with COVID-19 risk reduction after mRNA boosters. Learn how this impacts vaccine strategies against emerging variants.

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...